Oramed Pharmaceuticals (ORMP) Insider Trading & Ownership $2.31 -0.01 (-0.43%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oramed Pharmaceuticals (NASDAQ:ORMP) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage13.70%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$293,240.00Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$167,228.75 Get ORMP Insider Trade Alerts Want to know when executives and insiders are buying or selling Oramed Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ORMP Insider Buying and Selling by Quarter Oramed Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/10/2025Brad KnottU.S. Congress Member (R-NC)Sell$2.39$15,001 - $50,0003/16/2023Nadav KidronCEOBuy26,000$2.04$53,040.00 3/14/2023Nadav KidronCEOBuy100,000$2.01$201,000.00 3/13/2023Yadin RozovDirectorBuy20,000$1.96$39,200.00 1/3/2023Michael RabinowitzInsiderSell13,325$12.55$167,228.75 (Data available from 1/1/2013 forward) ORMP Insider Trading Activity - Frequently Asked Questions Who is on Oramed Pharmaceuticals's Insider Roster? The list of insiders at Oramed Pharmaceuticals includes Michael Rabinowitz, Nadav Kidron, and Yadin Rozov. Learn more on insiders at ORMP. What percentage of Oramed Pharmaceuticals stock is owned by insiders? 13.70% of Oramed Pharmaceuticals stock is owned by insiders. Learn more on ORMP's insider holdings. Which members of congress are trading Oramed Pharmaceuticals? Brad Knott (R-NC) has sold shares of Oramed Pharmaceuticals in the last year totaling $32,500. Oramed Pharmaceuticals Key ExecutivesMr. Nadav Kidron Esq. (Age 50)President, CEO & Executive Chairman Compensation: $754.3kMr. David Silberman CPA (Age 40)CFO & Treasurer Compensation: $259.53kDr. Miriam Kidron Ph.D. (Age 84)Chief Scientific Officer & Director Compensation: $503.95kMr. Joshua Hexter (Age 54)Chief Operating & Business Officer Compensation: $326.94k More Insider Trading Tools from MarketBeat Related Companies Sana Biotechnology Insider Trading Erasca Insider Trading Oruka Therapeutics Insider Trading ORIC Pharmaceuticals Insider Trading Checkpoint Therapeutics Insider Trading Tectonic Therapeutic Insider Trading REGENXBIO Insider Trading Olema Pharmaceuticals Insider Trading Benitec Biopharma Insider Trading COMPASS Pathways Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold This page (NASDAQ:ORMP) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORMP Stock Free ORMP Stock Alerts